13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
38 檔
37.7%
In Q1 2026, Rosalind Advisors, Inc.'s U.S. equity holdings reached a combined market value of $269.2M, distributed across 38 disclosed stock positions.
Rosalind Advisors, Inc. executed strategic sector rebalancing during Q1 2026, establishing 12 new positions while fully exiting 16 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 12.31% | +3.13% | — | |
| 2 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 7.53% | +1.03% | +53.04% | |
| 3 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 7.19% | +5.54% | +11.28% | |
| 4 | SVRA | Savara Inc | Stock-Other | 7.03% | +0.24% | -5.88% | |
| 5 | PCVX | Vaxcyte Inc | Stock-Other | 6.77% | -2.45% | — | |
| 6 | EYPT | Eyepoint Inc | Stock-Other | 5.37% | -0.12% | +50.25% | |
| 7 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 5.33% | +0.25% | +23.36% | |
| 8 | VOR | Vor Biopharma Inc | Stock-Other | 5.02% | -0.58% | — | |
| 9 | ✓ | Mediwound LTD | Stock-Other | 4.85% | -0.76% | — | |
| 10 | VSTM | Verastem Inc | Stock-Other | 4.55% | +1.11% | +19.57% | |
| 11 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.21% | -1.45% | — | |
| 12 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 3.53% | -0.85% | — | |
| 13 | HELP | Cybin Inc | Stock-Other | 2.95% | +1.85% | -7.59% | |
| 14 | CGON | Cg Oncology Inc | Stock-Other | 2.72% | -2.72% | EXIT | |
| 15 | NSPR | Inspiremd Inc | Stock-Other | 2.56% | -1.54% | — | |
| 16 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 2.53% | -0.68% | — | |
| 17 | PROF | Profound Medical CORP | Stock-Other | 2.16% | -0.11% | -22.53% | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.97% | -1.97% | EXIT | |
| 19 | ✓ | Replimune Group Inc | Stock-Other | 1.10% | -1.10% | EXIT | |
| 20 | ✓ | Polypid LTD | Stock-Other | 1.05% | -0.32% | -14.16% | |
| 21 | MYO | Myomo Inc | Stock-Other | 1.04% | +0.37% | +0.20% | |
| 22 | TLPH | Talphera Inc | Stock-Other | 1.01% | +0.97% | -6.30% | |
| 23 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.99% | +0.12% | — | |
| 24 | DFTX | Definium Therapeutics Inc | Stock-Other | 0.95% | -0.95% | EXIT | |
| 25 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.74% | -0.49% | -39.25% | |
| 26 | LPCN | Lipocine Inc | Stock-Other | 0.71% | -0.71% | EXIT | |
| 27 | NRXS | Neuraxis Inc | Stock-Other | 0.68% | +0.42% | — | |
| 28 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.45% | -0.45% | EXIT | |
| 29 | ANNX | Annexon Inc | Stock-Other | 0.45% | -0.45% | EXIT | |
| 30 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 0.42% | -0.42% | EXIT | |
| 31 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.42% | -0.03% | — | |
| 32 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 0.39% | -0.39% | EXIT | |
| 33 | BFRI | Biofrontera Inc | Stock-Other | 0.38% | +0.07% | +2.03% | |
| 34 | KURA | Kura Oncology Inc | Stock-Other | 0.33% | +0.08% | — | |
| 35 | ✓ | Regentis Biomaterials LTD | Stock-Other | 0.31% | +0.61% | — | |
| 36 | ✓ | Viridian Therapeutics Inc | Stock-Other | 0.02% | -0.02% | EXIT | |
| 37 | ✓ | Uniqure NV | Stock-Other | — | — | EXIT | |
| 38 | ✓ | Arrivent Biopharma Inc | Stock-Other | — | — | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XERS | Xeris Biopharma Holdings Inc | +1.7% | +53.04% | Add |
| 2 | XFOR | X4 Pharmaceuticals Inc | +1.7% | +23.36% | Add |
| 3 | ✓ | Replimune Group Inc | +1.1% | +452.45% | Add |
| 4 | EYPT | Eyepoint Inc | +0.9% | +50.25% | Add |
| 5 | DCTH | Delcath Systems Inc | +0.7% | — | Unchanged |
| 6 | NRXS | Neuraxis Inc | +0.3% | — | Unchanged |
| 7 | BFRI | Biofrontera Inc | +0.2% | +2.03% | Add |
| 8 | FENC | Fennec Pharmaceuticals Inc | +0.1% | +11.28% | Add |
| 9 | NSPR | Inspiremd Inc | +0.1% | — | Unchanged |
| 10 | OKUR | Onkure Therapeutics Inc-a | — | -39.25% | Trim |
| 11 | ✓ | Mediwound LTD | 0% | — | Unchanged |
| 12 | ✓ | Polypid LTD | 0% | -14.16% | Trim |
| 13 | ✓ | Uniqure NV | 0% | +195.80% | Add |
| 14 | KURA | Kura Oncology Inc | 0% | — | Unchanged |
| 15 | SVRA | Savara Inc | -0.2% | -5.88% | Trim |
| 16 | MYO | Myomo Inc | -0.2% | +0.20% | Add |
| 17 | ✓ | Arrivent Biopharma Inc | -0.2% | +0.93% | Add |
| 18 | ✓ | Spdr S&P 500 Etf Tr Put Option | -0.3% | -75.49% | Trim |
| 19 | ✓ | Regentis Biomaterials LTD | -0.3% | — | Unchanged |
| 20 | VSTM | Verastem Inc | -0.3% | +19.57% | Add |
| 21 | TLPH | Talphera Inc | -0.4% | -6.30% | Trim |
| 22 | ✓ | Invesco QQQ Tr Put Option 06/2 | -0.6% | -44.44% | Trim |
| 23 | PROF | Profound Medical CORP | -0.8% | -22.53% | Trim |
| 24 | CGON | Cg Oncology Inc | -1.7% | -66.67% | Trim |
| 25 | HELP | Cybin Inc | -1.8% | -7.59% | Trim |
| 26 | VRDN | Viridian Therapeutics Inc | -3% | -44.36% | Trim |
| 27 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 28 | REPL | Replimune Group Inc | — | EXIT | Sold out |
| 29 | ATYR | Atyr Pharma Inc | — | EXIT | Sold out |
| 30 | VOR | Vor Biopharma Inc | — | NEW | New buy |
| 31 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 32 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 33 | BRD1EUR | Mind Medicine Mindmed Inc | — | EXIT | Sold out |
| 34 | BCRX | Biocryst Pharmaceuticals Inc | — | NEW | New buy |
| 35 | AVIR | Atea Pharmaceuticals Inc | — | NEW | New buy |
| 36 | OCUL | Ocular Therapeutix Inc | — | EXIT | Sold out |
| 37 | AVBP | Arrivent Biopharma Inc | — | EXIT | Sold out |
| 38 | OVID | Ovid Therapeutics Inc | — | NEW | New buy |
| 39 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 40 | ✓ | Anavex Life Sciences CORP | — | EXIT | Sold out |
| 41 | LPCN | Lipocine Inc | — | NEW | New buy |
| 42 | ✓ | Spdr Series Trust | — | EXIT | Sold out |
| 43 | TRVI | Trevi Therapeutics Inc | — | EXIT | Sold out |
| 44 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 45 | ✓ | Ishares Tr | — | EXIT | Sold out |
| 46 | ANNX | Annexon Inc | — | NEW | New buy |
| 47 | AQST | Aquestive Therapeutics Inc | — | NEW | New buy |
| 48 | GUTS | Fractyl Health Inc | — | EXIT | Sold out |
| 49 | ✓ | Verastem Inc | — | EXIT | Sold out |
| 50 | ✓ | Viridian Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 38 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, XERS, FENC) accounted for 37.7% of total reported equity market value during Q1 2026.
Top New Position Initiated
PCVX
市值: $16.9M
Top Position Liquidated / Trimmed
REPL
前期市值: $13.7M
During Q1 2026, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (12.3%)、XERS (7.5%)、FENC (7.2%). The largest single position, DCTH, represented 12.3% of total portfolio value.
In Q1 2026, Rosalind Advisors, Inc. made 48 total portfolio adjustments, initiating 12 new buys, adding to 10 positions, trimming 10 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.